Loading
eRapa is a new form of the drug rapamycin from Biodexa Pharmaceuticals, designed to be absorbed more reliably. It is in a large trial in an inherited condition that causes many bowel polyps, and a smaller trial in early bladder cancer.
eRapa, licensed by Biodexa Pharmaceuticals from Emtora Biosciences in April 2024, is in a double-blind, placebo-controlled registrational phase 3 study in 168 patients with familial adenomatous polyposis, randomised 2:1, at about 30 sites in the United States and Europe; the first patients enrolled in August 2025 and recruitment passed the half-way point in August 2026. An investigator-initiated phase 2 study in non-muscle invasive bladder cancer is being conducted by the University of Texas, San Antonio. Biodexa announced FDA fast track designation for eRapa on 10 February 2025.
A formulation of rapamycin, an mTOR inhibitor, using nanotechnology and pH-sensitive polymers to improve its bioavailability and reduce variable pharmacokinetics and toxicity, as described by Biodexa Pharmaceuticals. Connects to mTOR.
1.eRapa slips into a pocket on mTOR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"eRapa" OR ABSTRACT:"eRapa" OR TITLE:"encapsulated rapamycin" OR ABSTRACT:"encapsulated rapamycin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about eRapa, not a curated reading list.
Shares Biodexa Pharmaceuticals and the tag pipeline.
Shares mTOR and the tag pipeline.
Shares mTOR and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/